Exobiosphere and Voyager Technologies: A Partnership for Space-Based Research and Drug Development
The collaboration between Exobiosphere and Voyager Technologies is a significant development in the field of space-based research and drug development. Exobiosphere, a Luxembourg-based space biotech firm, has designed an Orbital High-Throughput Screening Device, an automated mini lab that can fit into standard mid-deck lockers aboard crewed or uncrewed space stations. This device can autonomously keep organ cells alive and deliver therapeutics, allowing for more experiments to be conducted in space and faster results to be delivered back to Earth.
The partnership with Voyager Technologies Europe will enable Exobiosphere to conduct research aboard the International Space Station (ISS). This is a crucial development, as the CEO of Exobiosphere, Kyle Acierno, notes that "six months in space is equivalent to a decade on Earth in disease progression." This means that space could be the best place to study how diseases progress, and the faster results could lead to breakthroughs in drug development.
One of the key benefits of this partnership is the ability to take astronauts out of the loop, allowing for more experiments to be conducted in space. This is particularly important for biotech firms who want to accelerate or differentiate their research. Exobiosphere plans to expand its customer base to include these firms, as well as hospitals and academic institutions.
The partnership with Voyager Technologies is just one of several recent developments for Exobiosphere. The company has also signed a contract with the European Space Agency (ESA) to operate biotech experiments aboard the Haven-1 space station, which is set to fly next year. This contract includes an end-to-end mission, including selecting science experiments, preparing for the mission, overseeing the experiments in orbit, and returning data to Earth.
Exobiosphere also has ambitions beyond low Earth orbit (LEO), including studying what NASA's plans for a permanent lunar base could mean for astronaut health. The company is developing a system to study disease progression on the Moon, as the longest a human has spent on the lunar surface is 72 hours. This system could help us understand how humans can survive in orbit, on the Moon, and eventually on Mars.
In conclusion, the partnership between Exobiosphere and Voyager Technologies is a significant development in the field of space-based research and drug development. It has the potential to accelerate the pace of scientific discovery and lead to breakthroughs in drug development. The company's ambitions beyond LEO and its focus on studying disease progression in space and on the Moon make it a key player in the future of space exploration and research.
